Newsletter Subject

Biotech stock soars 195% on FDA green light 🚀

From

elitetrade.club

Email Address

adam@elitetrade.club

Sent On

Tue, Sep 26, 2023 12:19 PM

Email Preheader Text

Good Morning! Hey, there! It's Chris from Elite Trade Club, here to give you this morning's premarke

Good Morning! Hey, there! It's Chris from Elite Trade Club, here to give you this morning's premarket trading news. It's Tuesday, September 26th. I hope you have a great day. Now, let's get ready to trade! Markets 📈 Stocks kicked off the trading week with modest gains on Monday. The Nasdaq, S&P 500, and Russell 2K added 0.4%, while the Dow trailed with a 0.1% advance. Today, S&P 500 futures are down 0.3% in early premarket trading Sponsored [The AI Singularity Clock Is Ticking]( The dot-com crash… the COVID crash… but we've still never seen anything like what's next for artificial intelligence in the next few months. It's called the Singularity – and it refers to the exact millisecond when AI breaks free from its shackles to grow BILLIONS of times more powerful than humans. [Click here to get on the right side of this historic event.]( Premarket Highlights 🔎 ⚪ None No major news to report in today's premarket. What to Watch Today 👀 Housing Market Update With mortgage rates soaring and inventories crashing, the housing market is feeling the pressure from higher rates. Today, we'll get updated data on the S&P Case-Schiller Home Price Index and new home sales that could shed some light on the current state of the residential real estate market. With mortgage rates recently eclipsing the 8.0% mark, it'll be interesting to see how higher rates are impacting home prices. Major Earnings 💰 Cintas Corporation [CTAS] ... AM Ferguson Plc [FERG] ... AM TD Synnex Corporation [SNX] ... AM United Natural Foods, Inc. [UNFI] ... AM Costco Wholesale Corporation [COST] ... PM Progress Software Corporation [PRGS] ... PM AAR Corp. [AIR] ... PM Millerknoll, Inc. [MLKN] ... PM Mei Pharma, Inc. [MEIP] ... PM Economy 🏗 - S&P Case-Shiller home price index [Jul] ... 9:00a - New home sales [Aug] ... 10a - Consumer confidence [Sep] ... 10:00a Running Hot 🔥 Gainers - Tharimmune [THAR] >> +56.3% - Avalo Therapeutics [AVTX] >> +28.1% - 7GC Holdings [VII] >> +31.5% - Infobird [IFBD] >> +24.2% Decliners - Transcode Therapeutics [RNAZ] >> (69.8%) - Conduit Pharma [CDT] >> (20.0%) - PolishedCom [POL] >> (19.4%) - United Natural Foods [UNFI] >> (19.3%) Garmin [GRMN] - Last Close: $105.40 An industry award is lifting shares of Garmin. This morning, the GPS pioneer was named the 2023 Manufacturer of the Year by the National Marine Electronic Association. Garmin received the award at the NMEA's annual conference in Orlando, FL last week. Manufacturer of the Year honors are awarded to companies based on excellence in product service and support in the field. GRMN is leading the S&P 500 with a 2.8% gain on the news. My Take: GRMN is having a lot of trouble breaking through $107.50. It's currently above that mark, and, if it can hold on through the close, it could find new support at this level. Immunovant [IMVT] - Last Close: $20.28 Immunovant is trending after a clinical update. This morning, the small-cap biotech firm said IMVT-1402 produced a reduction in Immunoglobulin G in a Phase 1 trial. The drug candidate is currently being study as an inhibitor with a potential use in treating autoimmune diseases. IMVT-1402 also showed similar or greater potency compared with batoclimab, another candidate from Immunovant. IMVT is one of today's top stocks with a 63.9% gain on active trading volume. My Take: IMVT has been volatile as of late, but it has a solid positive trend line even before today's rally. Now, it's on pace to set a new 52-week high. There could be more gains ahead, but be wary of a pullback. Soleno Therapeutics [SLNO] - Last Close: $4.43 Soleno Therapeutics is also racking up gains after a clinical update. The tiny biopharma firm announced positive, statistically significant top-line data from a randomized study of DCCR for Prader-Willis syndrome. The study, dubbed C602, met its primary endpoint by producing a significant change in AQ-CT compared to placebo. Soleno CEO Anish Bhatnagar said the study's findings will support the filing of a new drug application with the FDA by the middle of next year. SLNO is a breakout performer this morning, with a 145.8% gain on elevated volume. My Take: It sounds like this study set SLNO up for a potential drug approval down the road, but it will take some time for the entire regulatory process to shake out. I expect we'll see some volatility here in the coming days and weeks. Femasys [FEMY] - Last Close: $0.3316 Femasys is rallying after an FDA green light. Monday evening, the micro-float biotech said it received clearance from the FDA to begin marketing its innovative FemaSeed infertility treatment. The FemaSeed intratubal artificial insemination procedure has already been approved in Canada. The procedure also works with Femasys' FemVue FDA-cleared diagnostic device for in-office ultrasound assessment of Fallopian tubes. FEMY tripled on the news, but it's beginning to pull back. Shares are currently up 195.9% on active elevated premarket trading volume. My Take: This could be a game-changing procedure for FEMY. I wouldn't be surprised if there are some Big Pharma players eyeing it for a potential acquisition. This stock could be an excellent speculative biotech play. That's it for today! Thanks for reading, and good luck out there! Best Regards, Chris D. -- Elite Trade Club P.S... Want alerts delivered straight to your cell every morning for free?* Text ELITE to 47121 to sign up now and get our watchlists sent directly to your phone! Or text CLOSE to 47121 to get on the mobile alert list for our Closing Bell Roundup report, featuring the day's top winners and losers. *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside of these emails. [Bots click here]( 1969 S. ALAFAYA TRAIL Orlando FL 32828 USA [Unsubscribe]( | [Change Subscriber Options](

Marketing emails from elitetrade.club

View More
Sent On

08/12/2024

Sent On

07/12/2024

Sent On

06/12/2024

Sent On

06/12/2024

Sent On

03/12/2024

Sent On

03/12/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.